These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37114884)

  • 21. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.
    Lejeune J; Piègu B; Gouilleux-Gruart V; Ohresser M; Watier H; Thibault G
    MAbs; 2012; 4(6):784-7. PubMed ID: 23032993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
    Shepshelovich D; Townsend AR; Espin-Garcia O; Latifovic L; O'Callaghan CJ; Jonker DJ; Tu D; Chen E; Morgen E; Price TJ; Shapiro J; Siu LL; Kubo M; Dobrovic A; Ratain MJ; Xu W; Mushiroda T; Liu G
    Cancer Med; 2018 Nov; 7(11):5478-5487. PubMed ID: 30318772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Charfi R; Rouached L; Bouden S; Tekaya R; Saidane O; Abdelmoula L; Sfar I
    Br J Clin Pharmacol; 2023 Jun; 89(6):1834-1843. PubMed ID: 36609675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis.
    Li G; Gao L; Ma R; Tian W; Mingzhi L
    Scand J Immunol; 2019 May; 89(5):e12758. PubMed ID: 30786049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A.
    Kyogoku C; Tsuchiya N; Matsuta K; Tokunaga K
    Genes Immun; 2002 Dec; 3(8):488-93. PubMed ID: 12486608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations.
    Weersma RK; Crusius JB; Roberts RL; Koeleman BP; Palomino-Morales R; Wolfkamp S; Hollis-Moffatt JE; Festen EA; Meisneris S; Heijmans R; Noble CL; Gearry RB; Barclay ML; Gómez-Garcia M; Lopez-Nevot MA; Nieto A; Rodrigo L; Radstake TR; van Bodegraven AA; Wijmenga C; Merriman TR; Stokkers PC; Peña AS; Martín J; Alizadeh BZ
    Inflamm Bowel Dis; 2010 Dec; 16(12):2080-9. PubMed ID: 20848524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
    Norton N; Olson RM; Pegram M; Tenner K; Ballman KV; Clynes R; Knutson KL; Perez EA
    Cancer Immunol Res; 2014 Oct; 2(10):962-9. PubMed ID: 24989892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
    Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
    Mendrinou E; Patsatsi A; Zafiriou E; Papadopoulou D; Aggelou L; Sarri C; Mamuris Z; Kyriakou A; Sotiriadis D; Roussaki-Schulze A; Sarafidou T; Vasilopoulos Y
    Pharmacogenomics J; 2017 Jun; 17(3):237-241. PubMed ID: 27044681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.
    Morgan AW; Robinson JI; Barrett JH; Martin J; Walker A; Babbage SJ; Ollier WE; Gonzalez-Gay MA; Isaacs JD
    Arthritis Res Ther; 2006; 8(4):R109. PubMed ID: 16846526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-nucleotide polymorphisms and copy number variations of the
    Moriya H; Saito K; Helsby N; Hayashi N; Sugino S; Yamakage M; Sawaguchi T; Takasaki M; Takahashi M; Kurosawa N
    Biomed Rep; 2014 Mar; 2(2):265-269. PubMed ID: 24649108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S
    PLoS One; 2015; 10(4):e0122088. PubMed ID: 25848939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
    Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
    mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
    Dahan L; Norguet E; Etienne-Grimaldi MC; Formento JL; Gasmi M; Nanni I; Gaudart J; Garcia S; Ouafik L; Seitz JF; Milano G
    BMC Cancer; 2011 Nov; 11():496. PubMed ID: 22117530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of FCGR2A and FCGR3A variants on CLL outcome.
    Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
    Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
    Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
    Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
    Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
    EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.